Clinical Consequences of Using an Indeterminate Range for Early Infant Diagnosis of HIV: A Decision Model.
Journal
Journal of acquired immune deficiency syndromes (1999)
ISSN: 1944-7884
Titre abrégé: J Acquir Immune Defic Syndr
Pays: United States
ID NLM: 100892005
Informations de publication
Date de publication:
01 11 2019
01 11 2019
Historique:
entrez:
15
10
2019
pubmed:
15
10
2019
medline:
15
5
2020
Statut:
ppublish
Résumé
To minimize false-positive diagnoses of HIV in exposed infants, the World Health Organization recommends confirmatory testing for all infants initiating antiretroviral therapy (ART). In settings where confirmatory testing is not feasible or intermittently performed, clinical decisions may be aided by semi-quantitative cycle thresholds (Cts) that identify positive results most likely to be false-positive. We developed a decision analysis model of HIV-exposed infants in sub-Saharan Africa to estimate the clinical consequences of deferring ART for infants with weakly positive ("indeterminate") results. We assessed the degree to which "indeterminate" results may reduce the number of infants starting ART unnecessarily while missing a small number of HIV-infected infants. Our primary outcome was the ratio of averted unnecessary ART regimens to additional HIV-related deaths (due to false-negative diagnosis) at different Ct cutoffs. The clinical consequences of adopting an indeterminate range varied with the prevalence of HIV and Ct cutoff. Considering a Ct cutoff ≥33, adopting an indeterminate range could prevent a median of 1.4 infants from receiving ART unnecessarily (95% UR: 1.0-2.0) for each additional HIV-related death. This ratio could be improved by prioritizing infants with indeterminate results for confirmatory testing [median 8.8 (95% UR: 6.0-13.3)] and by adopting a higher cutoff [median 82.3 (95% UR: 49.0-155.8) with Ct ≥36]. When implemented in settings where confirmatory testing is not universal, the benefits of classifying weakly positive results as "indeterminate" may outweigh the risks. Accordingly, the World Health Organization has recommended Ct values ≥33 be considered indeterminate for infant HIV diagnosis.
Sections du résumé
BACKGROUND
To minimize false-positive diagnoses of HIV in exposed infants, the World Health Organization recommends confirmatory testing for all infants initiating antiretroviral therapy (ART). In settings where confirmatory testing is not feasible or intermittently performed, clinical decisions may be aided by semi-quantitative cycle thresholds (Cts) that identify positive results most likely to be false-positive.
METHODS
We developed a decision analysis model of HIV-exposed infants in sub-Saharan Africa to estimate the clinical consequences of deferring ART for infants with weakly positive ("indeterminate") results. We assessed the degree to which "indeterminate" results may reduce the number of infants starting ART unnecessarily while missing a small number of HIV-infected infants. Our primary outcome was the ratio of averted unnecessary ART regimens to additional HIV-related deaths (due to false-negative diagnosis) at different Ct cutoffs.
RESULTS
The clinical consequences of adopting an indeterminate range varied with the prevalence of HIV and Ct cutoff. Considering a Ct cutoff ≥33, adopting an indeterminate range could prevent a median of 1.4 infants from receiving ART unnecessarily (95% UR: 1.0-2.0) for each additional HIV-related death. This ratio could be improved by prioritizing infants with indeterminate results for confirmatory testing [median 8.8 (95% UR: 6.0-13.3)] and by adopting a higher cutoff [median 82.3 (95% UR: 49.0-155.8) with Ct ≥36].
CONCLUSIONS
When implemented in settings where confirmatory testing is not universal, the benefits of classifying weakly positive results as "indeterminate" may outweigh the risks. Accordingly, the World Health Organization has recommended Ct values ≥33 be considered indeterminate for infant HIV diagnosis.
Identifiants
pubmed: 31609928
doi: 10.1097/QAI.0000000000002155
pii: 00126334-201911010-00009
pmc: PMC7734593
mid: NIHMS1647755
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
287-296Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Organisme : NIAID NIH HHS
ID : P30 AI094189
Pays : United States
Références
J Med Virol. 2014 Jan;86(1):82-7
pubmed: 24136657
AIDS. 2018 Jul 17;32(11):1453-1463
pubmed: 29746301
BMC Public Health. 2013 Apr 01;13:286
pubmed: 23547782
South Afr J HIV Med. 2016 May 13;17(1):451
pubmed: 29568610
J Clin Virol. 2012 Feb;53(2):106-9
pubmed: 22196872
Clin Infect Dis. 2009 Dec 15;49(12):1915-27
pubmed: 19916798
Int J Epidemiol. 2011 Apr;40(2):385-96
pubmed: 21247884
Lancet. 2004 Oct 2-8;364(9441):1236-43
pubmed: 15464184
Pediatrics. 2011 Feb;127(2):e423-41
pubmed: 21262891
PLoS Med. 2017 Nov 21;14(11):e1002446
pubmed: 29161262
J Clin Virol. 2017 Oct;95:86-89
pubmed: 28898704
Lancet Infect Dis. 2014 Jul;14(7):650-5
pubmed: 24456814
S Afr Med J. 2012 Feb 23;102(3 Pt 1):149-52
pubmed: 22380909
PLoS One. 2017 Feb 24;12(2):e0171917
pubmed: 28234969
Medicine (Baltimore). 2017 Oct;96(40):e8055
pubmed: 28984760
J Clin Microbiol. 2009 Apr;47(4):889-95
pubmed: 19193837
PLoS One. 2013;8(3):e59906
pubmed: 23527284
Diagn Microbiol Infect Dis. 2018 Jul;91(3):248-255
pubmed: 29655874
S Afr Med J. 2014 Jun 19;104(8):574-7
pubmed: 25213851
J Clin Virol. 2014 Aug;60(4):392-8
pubmed: 24906641
J Acquir Immune Defic Syndr. 2018 Feb 1;77(2):212-216
pubmed: 29084045
Lancet. 2018 Nov 10;392(10159):1859-1922
pubmed: 30415748